Manufacturing roundup: mRNA manufacturer nets $300M+ investment to scale research; Cytiva acquires Michigan facility
As mRNA tech has been made more popular by the Covid-19 pandemic, investor cash is making its way to manufacturers and researchers.
In their latest move, Irish biotech Normax Biomed has netted a €300 Million, or $305 million, investment from private firm GEM Global Yield.
The deal will see GEM provide Normax with a share subscription facility of up to €50 Million for a 36-month term following the public listing of the Normax common stock.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.